Compare TLF & NEUP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TLF | NEUP |
|---|---|---|
| Founded | 1980 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Apparel | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.5M | 20.6M |
| IPO Year | 2006 | 2002 |
| Metric | TLF | NEUP |
|---|---|---|
| Price | $2.64 | $3.94 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $21.00 |
| AVG Volume (30 Days) | 24.6K | ★ 197.7K |
| Earning Date | 05-11-2026 | 05-23-2026 |
| Dividend Yield | ★ 32.05% | N/A |
| EPS Growth | ★ 1122.22 | N/A |
| EPS | ★ 0.08 | N/A |
| Revenue | ★ $76,324,000.00 | $15,649,448.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $32.38 | ★ N/A |
| Revenue Growth | ★ 2.60 | N/A |
| 52 Week Low | $2.20 | $3.19 |
| 52 Week High | $3.36 | $21.31 |
| Indicator | TLF | NEUP |
|---|---|---|
| Relative Strength Index (RSI) | 69.55 | 54.18 |
| Support Level | $2.27 | $3.75 |
| Resistance Level | $2.75 | $4.15 |
| Average True Range (ATR) | 0.09 | 0.17 |
| MACD | 0.02 | 0.03 |
| Stochastic Oscillator | 66.27 | 33.90 |
Tandy Leather Factory Inc is a specialty retailers of leather and leathercraft-related items. Its primary line of business is the sale of leather, leather crafts, and related supplies. Its broad line of leather and related products includes leather, leatherworking tools, leather dyes and finishes, and do-it-yourself kits. Its products include Leather, tools, Hardware, Supplies, Kits, Books and Patterns, and Gift cards. The company sells its products primarily through company-owned stores and through orders generated from its global websites, and through direct account representatives in its commercial division. Geographically the company operates within the United States, and Canada. it generates the highest revenue from the United States.
Neuphoria Therapeutics Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder. The Company operates through a single operating and reportable segment focused on the discovery and development of allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical need.